News for Tiziana Life Sciences Ltd Stock (TLSA)

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

GlobeNewsWire • 10/26/22

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

GlobeNewsWire • 10/19/22

Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023

Proactive Investors • 10/12/22

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

GlobeNewsWire • 10/12/22

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

GlobeNewsWire • 09/29/22

Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy

Proactive Investors • 09/28/22

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan

GlobeNewsWire • 09/28/22

Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment

Proactive Investors • 09/20/22

Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab

GlobeNewsWire • 09/20/22

Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS

Proactive Investors • 09/15/22

Tiziana Life Sciences Announces Grant received by the Brigham and Women's Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis

GlobeNewsWire • 09/15/22

Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference

Proactive Investors • 08/01/22

Tiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer's Disease

GlobeNewsWire • 08/01/22

Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately

Proactive Investors • 07/18/22

Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer

GlobeNewsWire • 07/18/22

Tiziana Life Sciences Announces Resignation of CEO

GlobeNewsWire • 07/15/22

Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

GlobeNewsWire • 06/09/22

Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient

Benzinga • 06/08/22

Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumab

Proactive Investors • 06/08/22

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

GlobeNewsWire • 06/08/22

Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs

GlobeNewsWire • 06/06/22

Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting

GlobeNewsWire • 06/01/22

Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance

GlobeNewsWire • 05/24/22